The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for CRISPR Therapeutics AG (CRSP) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.02, or 0.03%, to $72.20. The CRISPR Therapeutics AG has recorded 29,943 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia.
CRISPR Therapeutics AG is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $72.18 and fluctuated between $76.19 as its day high and $68.10 as its day low. The current market capitalization of CRISPR Therapeutics AG is $5.73B. A total of 8.01 million shares were traded on the day, compared to an average of 1.50M shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, CRSP has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 18 BUYs and 28 SELLs from insiders. Insiders purchased 333,654 shares during that period but sold 221,626.
In the most recent transaction, Kulkarni Samarth sold 25,000 shares of CRSP for 64.88 per share on May 30. After the transaction, the Chief Executive Officer now owns 387,377 company shares. In a previous transaction on Apr 25, Kulkarni Samarth sold 25,000 shares at 50.67 per share. CRSP shares that Chief Executive Officer owns now total 387,377.
Among the insiders who sold shares, Kulkarni Samarth disposed of 25,000 shares on Mar 29 at a per-share price of $44.46. This resulted in the Chief Executive Officer holding 387,377 shares of CRSP after the transaction. In another insider transaction, Kulkarni Samarth sold 25,000 shares at $48.25 per share on Feb 27. Company shares held by the Chief Executive Officer now total 375,988.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for CRSP in the last 3 months, the mean price target is $87.78 with high estimates of $220.00 and low estimates of $42.00. In terms of 52-week highs and lows, CRSP has a high of $72.00 and a low of $37.55.
As of this writing, CRSP has an earnings estimate of -$0.35 per share for the current quarter. EPS was calculated based on a consensus of 21 estimates, with a high estimate of $1.25 per share and a lower estimate of -$2.09. The company reported an EPS of -$0.98 in the last quarter, which was 53.80% higher than expectations of -$2.12.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. CRSP’s latest balance sheet shows that the firm has $2.38B in Cash & Short Term Investments as of fiscal 2021. There were $225.03M in debt and $119.88M in liabilities at the time. Its Book Value Per Share was $21.75, while its Total Shareholder’s Equity was $2.40B.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CRSP is Buy with a score of 4.04.